On December 25th, the 8th Zhongguancun International Frontier Technology Competition in the biomedical field concluded successfully at the Dongsheng International Science Park in Zhongguancun. After intense competition and evaluation, Beijing Genecradle Therapeutics Technology Co., Ltd. stood out with its "Disruptive Gene Therapy Platform Technology Project for Children's Critical Genetic Diseases" and successfully made it to the TOP10 list in the biomedical field, earning the second place in this competition.

The Zhongguancun International Frontier Technology Competition is a high-level international competition platform jointly sponsored by the Beijing Municipal Science and Technology Commission, the Zhongguancun Science Park Management Committee, and the Zhongguancun Science City Management Committee. The event seeks the world's most outstanding hard technologies through a process of "global invitation, free exploration, and public roadshows," selecting enterprises and teams with internationally leading frontier technologies, and creating a high-level platform for the display and exchange of frontier technologies. 

Genecradle Therapeutics' excellent performance in this competition not only demonstrated its profound technical accumulation and strong innovation capabilities in the field of gene therapy but also highlighted its responsibility and mission as a biomedical enterprise. In the future, Genecradle Therapeutics will continue to adhere to a spirit of innovation and pragmatism, continuously deepening technology research and development, expanding application fields, and bringing hope and good news to more patients with genetic diseases.

Dr. Wang Qianyi, Head of Public Affairs at Genecradle Therapeutics, represented the company in the competition.